News | November 23, 2010

Balloon Catheter Surpasses Filter-Based Systems for Treating Lower Extremity Embolisms

November 23, 2010 – A device for peripheral transluminal angioplasty (PTA) and for capturing and containing embolic material during angioplasty in the lower extremities has been approved by the U.S. Food and Drug Administration (FDA). The Proteus device, by Angioslide, can be used in the femoral, iliac, iliofemoral, popliteal, tibial, peroneal and profunda arteries.

“One of the most devastating complications arising from peripheral transluminal angioplasty is embolic material that escapes to a point that is anatomically distant from the location of the embolism,” said Gunnar Tepe, M.D., head of diagnostic and interventional radiology at the Academic Hospital of Rosenheim (Rosenheim, Germany). “Such complications can lead to a spectrum of consequences up to an including the loss of limb or life.”

Filter-based systems of embolic protection have several advantages and have been the primary mechanism for capturing embolic debris. However, limitations include the ability to deliver the filter, the added cost, lack of FDA clearance for infrainguinal use and filter-caused arterial trauma.

The device is used as an angioplasty balloon, with a technical success rate of 97 percent to 99 percent, and a pooled clinically significant vessel dissection rate of less than 5 percent. Porcine models have shown that there is no increased vessel injury from the inrolling mechanism of the balloon.

It combines the ability to perform angioplasty while also capturing debris that could potentially embolize during the procedure. Initially, the device functions as a normal angioplasty balloon. After angioplasty, the balloon is deflated to 2 atm., when arterial flow remains occluded. The balloon is then infolded upon itself, essentially sucking up potential embolic debris.

For more information:

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init